

# CO<sub>2</sub> Effects in Space

Relationship to Intracranial Hypertension

# CO<sub>2</sub> Effects Terrestrially

- ▶ Terrestrial atmospheric CO<sub>2</sub> level is 0.039% (0.30 mmHg)
- ▶ Above 2% (**15.2 mmHg, 20,000 ppm**), carbon dioxide may cause a feeling of heaviness in the chest and/or more frequent and deeper respirations.
  - ▶ If exposure continues at that level for several hours, minimal "acidosis" (an acid condition of the blood) may occur but more frequently is absent.
  - ▶ The concentration of carbon dioxide usually must be over about 2% (20,000 ppm) before most people are aware of its presence unless the odor of an associated material (auto exhaust or fermenting yeast, for instance) is present at lower concentrations.
- ▶ **Breathing rate** doubles at 3% (**22.8 mmHg, 30,000 ppm**) CO<sub>2</sub> and is four times the normal rate at **5% (38 mmHg, 50,000 ppm)** CO<sub>2</sub>. **At levels above 5%, concentration CO<sub>2</sub> is directly toxic.** [At lower levels we may be seeing effects of a reduction in the relative amount of oxygen rather than direct toxicity of CO<sub>2</sub>.]

# Terrestrial Effects

- Symptoms of high or prolonged exposure to carbon dioxide include -rapid breathing, diminished mental alertness, impaired muscular coordination, faulty judgment, depression of all sensations, emotional instability, and fatigue.
- As intoxication progresses, nausea, vomiting, prostration, and loss of consciousness may result.
- Eventually this leads to convulsions, coma, and death.

Main symptoms of

# Carbon dioxide toxicity

**Volume %  
in air**

- - 1%
- - 3%
- - 5%
- - 8%

**Visual**

- Dimmed sight

**Auditory**

- Reduced hearing

**Central**

- Drowsiness
- Mild narcosis
- Dizziness
- Confusion
- Headache
- Unconsciousness

**Skin**

- Sweating

**Respiratory**


- Shortness of breath

**Heart**

- Increased heart rate and blood pressure

**Muscular**

- Tremor



# Research Terrestrially - Navy Data

- Animal Models

- Animal model- 1.5% (**11.19 mmHg**) CO<sub>2</sub> increased incidence of focal and tubular kidney calcification
- Animal model 2 –at 1.5% (**11.19 mmHg**) showed significant bone loss of calcium and phosphorus with the commensurate increase in bone bicarbonate to compensate for acidosis.

- Human Data

- Subject Exposure to 1.5% (**11.19 mmHg**) CO<sub>2</sub> – 42 days increased red cell calcium and renal excretion of Phosphorus. Calcium effect on cell membrane similar to narcosis

# Research Terrestrially – Navy Data

- Submarine Patrol Data
  - Ten year comparison with Surface Vessels – Increase rate Respiratory, GI, Urologic, and EENT illnesses.  $\text{CO}_2 \geq 1\%$  (7.6 mmHg) Tansey and Schaefer
  - Royal Navy – Patrols with  $\text{CO}_2 \geq 1\%$  (7.6 mmHg) showed mild uncompensated respiratory acidosis with the respiratory parameters returning to normal. Pingre

# Terrestrial Research

- Animal Models

- Chronic exposure showed elevated CBF in sheep even after termination of the hypercapnia.

- Human

- Visuomotor decreases in performance with concentrations of as small as 1.2% (**9.12 mmHg**)

# Terrestrial Research


- Chronic Exposure model - 0.7% (**5.32 mmHg**) and 1.2% (**9.12 mmHg**)
  - Showed increased cerebral blood flow, lactic acid build up with exercise, and mild performance impairment
  - Initial response is increased ventilation volume, alveolar dead space, and respiratory rate. Respiratory rate and minute volume return to normal in 2 weeks, but  $\text{PaCO}_2$  and pH do not.
  - The CBF decreased after the initial exposure to a higher stabilized baseline. It was also noted that during the  $\text{CO}_2$  exposure visual stimulation increased the CBF 30%.
  - Headaches were more frequent at the beginning of the 1.2%  $\text{CO}_2$  trial.



# Terrestrial Research

- Chronic Exposure model - 0.7% (**5.32 mmHg**) and 1.2% (**9.12 mmHg**)
  - Cerebral autoregulatory mechanisms were preserved during sustained mild and intense exposure levels of hypercapnia (Tested reaction to 5% [38.0 mmHg] during the chronic adaptation phases).
  - The superimposition of Head Down Tilt (HDT) with its increased CBF did not alter CBF responses.
  - Cerebral blood flow responses were similar in amplitude and pattern at both 0.7% (**5.32 mmHg**) and 1.2% (**9.12 mmHg**) CO<sub>2</sub>.

# Changes in Space



# Physiological Changes with Microgravity

- Fluid shift to thorax and head – This results in intracranial pressure increases and congested cerebral circulation – increased CBF and Intravenous dilatation
- Plasma volume – decreased 17% in first 24 hours stabilizes to 15.9 %
- Red cell mass – decreased by 10-11%
- Cardiac output – decreased by 17-20%

# CO<sub>2</sub> Symptoms in space


- Primarily noted to be headache and visual changes.
- Noted onset at levels far lower than terrestrially
- Mission Control personnel noticed behavioral changes had occurred at lower levels in crewmembers.  
Procedural errors, unwarranted comments from crewmembers, and increased “aggrivation”
- EVA crewmembers “felt better” post initiation of Oxygen pre-breath and donning the suit (100% O<sub>2</sub> and 4.3 psi environment).

# CO<sub>2</sub> Symptoms in space

- CO<sub>2</sub> potent vasodilator
- Causes increased blood flow – problem in that the cerebral blood vessels are already congested
- Thought to be contributory to the symptoms occurring at lower levels.


# Mechanisms

## CO<sub>2</sub> Effects on Cerebral Blood Flow



# CSF Production

## Blood-CSF Interface in the Choroid Plexus



# Neuroendocrine targets of interest

| CHOROID PLEXUS AND POLYPEPTIDES                                  |   |                     |                              | 67 |
|--|---|---------------------|------------------------------|----|
| TABLE 1. Receptors Identified in the Choroid Plexus <sup>1</sup> |   |                     |                              |    |
| Ligand   | Receptor  | Method of detection | Selected references          |    |
| Angiotensin II   | AT <sub>1A</sub> , AT <sub>1B</sub>                             | ISH, RGE            | Chen et al. (1997)           |    |
| Apolipoprotein E   | apoER2  | ISH                 | Johren and Saavedra (1996)   |    |
| Apolipoprotein J/clusterin                                       | gp330/megalin   | IHC, RT-PCR         | Kim, D.-H., et al. (1996)    |    |
| Atrial natriuretic peptide                                       | NPR-A, NPR-C  | AR, ISH             | Chun et al. (1999)           |    |
| Bradykinin   | B <sub>2</sub>  | AR                  | Kounnas et al. (1994)        |    |
| Brain-derived neurotrophic factor                                | trkB, p <sup>75NTR</sup>  | IHC, RPA            | Brown and Zuo (1993)         |    |
| Corticotropin-releasing factor                                   | CRF-R2  | AR, ISH             | Herman et al. (1996)         |    |
| Endothelin   | ET <sub>A</sub> , ET <sub>B</sub>                               | ISH, NB, RBA        | Murone et al. (1996)         |    |
| Fibroblast growth factor   | FGFR1, FGFR2  | ISH                 | Timmusk et al. (1995)        |    |
| Growth hormone   | GHR   | RBA, RT-PCR         | Vega et al. (1992)           |    |
| Insulin  | Insulin receptor  | AR, ISH             | Chalmers et al. (1995)       |    |
| Insulin-like growth factor                                       | IGF-1R, IGF-2R  | AR, IHC, RBA        | Lacroix and Rivest (1996)    |    |
| Interleukin-1  | IL-1RI  | ISH                 | Sanchez et al. (1999)        |    |
| Leptin   | OB-Rb, OB-Rc, OB-Rf   | AR, ISH             | Angelova et al. (1996, 1997) |    |
| Nerve growth factor  | p <sup>75NTR</sup>  | IHC                 | Hori et al. (1992)           |    |
| Neurotrophin-4   | trkB, p <sup>75NTR</sup>  | IHC, RPA            | Gonzalez et al. (1995)       |    |
| Prolactin  | PRL-R   | IHC, ISH, RT-PCR    | Yazaki et al. (1994)         |    |
| Transforming growth factor-β                                     | TβRII   | ISH                 | Thörnwall et al. (1995)      |    |
| Vascular endothelial growth factor                               | VEGFR-1, VEGFR-2  | ISH                 | Zhai et al. (1994)           |    |
| Vasoactive intestinal polypeptide                                | VIP1, VIP2  | AR                  | Kar et al. (1993)            |    |
| Vasopressin  | V <sub>1a</sub> , V <sub>1b</sub> , V <sub>2</sub> <sup>2</sup> | ISH                 | Marks et al. (1990)          |    |

<sup>1</sup>AR = autoradiography; IHC = immunohistochemistry; ISH = in situ hybridization; NB = Northern blotting; RBA = receptor binding assay; RGE = reporter gene expression; RPA = RNase protection assay; RT-PCR = reverse transcriptase-polymerase chain reaction.

<sup>2</sup>Expressed only during development.




# What should we be looking for


- Arginine Vasopressin
- Atrial Natriuretic Peptide

# ANP Upregulated in Rat Choroid Plexus After 9 days Spaceflight (STS-40, 1994)

BRAIN ANP RECEPTORS IN RATS—HERBUTE E





BRAIN ANP RECEPTORS IN RATS—HERBUTE ET A




# ANP Expression Returns to Normal Values After Mission Length (ML) Recovery (9 days)

Lat Vent


Lat Vent



# STS-56 - 1995



Normal



Spaceflight, or Hind-Limb Unloading



Mission-Length Recovery Period